| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_979d4e27f8d5263b372f53ec07031bb3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5513 |
| filingDate |
2014-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_042d1bd8bb357c3ef5f8cbf23dcad634
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5272f85466b355d87916b1bc13bb6793 |
| publicationDate |
2016-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2014352875-A1 |
| titleOfInvention |
Gastrin antagonists (eg YF476, netazepide) for treatment and prevention of osteoporosis |
| abstract |
The provided embodiments are based in some aspects on the demonstration herein of a role for gastrin in regulating the aging gut-ovary axis and effects of targeting gastrin activity in reversing gastrin-mediated bone loss. Provided are methods, compositions and agents, including gastrin antagonists, e.g. CCK2 receptor antagonist (in particular YF476), for treatment, amelioration, and prevention of bone diseases and conditions. Methods for treating a bone disease or condition associated with hypergastrinemia in a subject in need thereof may comprise administering to the subject at least one dose of a therapeutically effective amount of a gastrin receptor-targeting agent, thereby treating the bone disease or condition associated with hypergastrinemia. |
| priorityDate |
2013-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |